Biotech Co.* (Country; Symbol)

Pharma Co. (Country)


Terms/Details (Date)

Altus Pharmaceuticals Inc. (ALTU)

Lonza Group Ltd. (Switzerland)

Deal for the commercial manufacture of Altus' ALTU-135 drug substances at Lonza's facility the Czech Republic

The oral enzyme replacement therapy for patients with pancreatic insufficiency is entering Phase III trials; terms of the deal were not disclosed (11/17)

Ambrilia Biopharma Inc. (Canada; TSX:AMB)

Various companies

Ambrilia entered deals for European sales of its sustained-release formulation of Octreotide for acromegaly

Archimedes Pharma Ltd. will distribute the product in the UK; Gerolymatos Group of Cos. in Greece, Turkey and other countries; Pharmis in Portugal and Brazil; and Kwidza Pharma GmbH in Austria (12/5)

BioServe Biotechnologies*

Merck Specialties Private Ltd. (Indian subsidiary of Merck KGaA; Germany)

MSPL will market and distribute BioServe's genomic products and services in India

The plan is to extend the distribution deal across Asia in 2007; terms were not disclosed (1/9)

Celgene Corp. (CELG)

Siegfried Ltd. (Switzerland)

Celgene acquired an active pharmaceutical ingredient manufacturing facility

Celgene is paying $46.5M in cash, with an initial payment of $12.5M; the facility initially will be used to produce Revlimid (12/11)

Crucell NV (the Netherlands; CRXL)

Abbott Laboratories

Non-exclusive STAR research license agreement for the production of monoclonal antibodies

Abbott would evaluate Crucell's STAR technology for generating cell lines for manufacture of biopharmaceuticals (1/31)

DiaKine Therapeutics Inc.*

AdPharma Inc.

Agreement to develop drugs aimed at reversing diabetes with the contract research firm AdPharma

Terms call for AdPharma to provide drug development services at a discount in exchange for an undisclosed number of DiaKine's common shares; AdPharma made an investment in DiaKine's convertible note (1/31)

DiaKine Therapeutics Inc.*

Mediatech Inc.

Deal to market DiaKine's Lisofylline to islet cell transplant centers worldwide

The product is designed to block autoimmune damage to insulin-producing cells; resulting revenues would be shared (1/10)

Durect Corp. (DRRX)

Hospira Worldwide Inc.

Manufacturing and supply agreement for POSIDUR, Durect's postsurgical pain management investigational drug

POSIDUR is a long-acting local anesthetic that is intended to be injected during surgery; Hospira will provide clinical and commercial supplies on a worldwide basis (1/29)

Gentium SpA (Italy; GENT)

Crinos SpA (Italy)

Gentium acquired Italian marketing authorizations for Defibrotide, which is being developed for veno-occulsive disease and other indications

Gentium is paying €8M up front and |8M more over two years; Crinos agreed to waive its right of first refusal to market the product in Europe for other indications; Crinos would get royalties on sales (1/3)

Helix BioPharma Corp. (Canada; TSX:HBP)

BioVectra (division of Diagnostic Chemicals Ltd.)

Deal under which BioVectra will manufacture L-DOS47 bulk drug product for human clinical testing

The preclinical product is a targeted agent for treating adenocarcinoma of the lung; terms of the deal were not disclosed (1/5)

Pharmaxis (Australia; PXSL)

Aldo-Union SA (Spain)

Aldo-Union will market and distribute Pharmaxis' asthma diagnostic and management tool, Aridol, in Spain

Specific terms were not disclosed (1/22)

Transgenomic Inc. (TBIO)

ARUP Laboratories

Strategic relationship in which Transgenomic will provide reference laboratory services to ARUP for the analysis of patient samples for mitochondrial DNA mutations, and mutations for other disorders

Transgenomic has developed expertise in analyzing the whole mitochondrial genome, and proprietary tools have allowed the company to detect mutations in samples with less than 5% of mutated DNA (1/31)

Trubion Pharmaceuticals Inc. (TRBN)

Laureate Pharma Inc.

Agreement to produce TRU-016, a protein for non-Hodgkin's lymphoma

Financial terms were not disclosed (1/30)

Unigene Laboratories Inc. (OTC BB:UGNE)

Novartis AG (Switzerland)

Supply agreement for the bulk peptide necessary to support Novartis' osteoporosis drug development program

Unigene will use its manufacturing technology to develop an FDA-compliant process for the peptide, and Novartis will have the chance to purchase additional quantities as necessary (1/29)

Vion Pharmaceuticals Inc. (VION)

Ben Venue Laboratories (unit of Boehringer Ingelheim GmbH; Germany)

Deal under which Ben Venue will manufacture Vion's cancer drug Cloretazine (VNP40101M)

The alkylating agent is in Phase II and III trials; terms of the deal were not disclosed (12/13)


# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange.